ライフサイエンスコーパス: activated platelet

1 latelet, but remodels and centralizes in the activated platelet.

2 n released by activated neutrophils binds to activated platelets.

3 ighlighted a role for secreted product(s) of activated platelets.

4 permitting storage and release of FVIII from activated platelets.

5 ts can be uncoupled from monocyte binding to activated platelets.

6 was overlaid with an unstable shell of less-activated platelets.

7 produced by megakaryocytes and released from activated platelets.

8 ndicating the release of certain miRNAs from activated platelets.

9 from 0.8 to 2.1% (p < 0.001) on addition of activated platelets.

10 expose TF within minutes when stimulated by activated platelets.

11 ed A11) capable of inducing fragmentation of activated platelets.

12 ytoskeletons isolated from either resting or activated platelets.

13 the surface of either thrombin- or collagen-activated platelets.

14 associated only with actin cytoskeletons of activated platelets.

15 CD40L), a proinflammatory marker released by activated platelets.

16 ASp-interacting protein (WIP) in resting and activated platelets.

17 ed a catalog of the components released from activated platelets.

18 ted the coating of quiescent leukocytes with activated platelets.

19 manipulated by changing the concentration of activated platelets.

20 microparticles, but not microparticles from activated platelets.

21 were found only on mouse microparticles from activated platelets.

22 with functional receptors on the surface of activated platelets.

23 e effectively by C1C2 than C2 for binding to activated platelets.

24 ar subdomain within factor XIa that binds to activated platelets.

25 amount of NO released from stimulated and/or activated platelets.

26 otential (Deltapsi(m)) in a subpopulation of activated platelets.

27 nt for endothelial cells that is released by activated platelets.

28 1 signaling prevents TF from accumulating in activated platelets.

29 Xa), and factor XIa complexes on PS-exposed activated platelets.

30 on system can be localized to the surface of activated platelets.

31 ich repeats, inhibited the binding of FXI to activated platelets.

32 of factor IX and IXa to thrombin- or SFLLRN-activated platelets.

33 site had no effect on the binding of FXI to activated platelets.

34 nase complex on the surfaces of vesicles and activated platelets.

35 referentially to adenosine diphosphate (ADP)-activated platelets.

36 a antagonists inhibit release of sCD40L from activated platelets.

37 sembly of the factor X-activating complex on activated platelets.

38 p in generating soluble EGF bioactivity from activated platelets.

39 ellular localization of PIP5K in resting and activated platelets.

40 e-rich repeats on the binding of 125I-FXI to activated platelets.

41 cule expressed on both endothelial cells and activated platelets.

42 production of 12-HETE-LPC and 12-HETE-LPE in activated platelets.

43 te in a nanoparticle state on the surface of activated platelets.

44 (cRGD) to enable highly selective binding to activated platelets.

45 me mainly from studies of a subpopulation of activated platelets.

46 bundled agglomerates tightly associated with activated platelets.

47 the main receptor for Efb on the surface of activated platelets.

48 organization of granules in unstimulated and activated platelets.

49 were massively infiltrated by aggregates of activated platelets.

50 d fibrinolytic drug that is directed against activated platelets.

51 ated platelets is covered by a shell of less-activated platelets.

52 at has recently been shown to be secreted by activated platelets.

53 GDV) that binds with GPIIb/IIIa expressed on activated platelets.

54 binding affinity of camouflaged tPA with the activated platelets.

55 hat, for optimal function in the presence of activated platelets, a preformed dimer of factor XI is n

56 ibution from enhanced levels of thrombin and activated platelets, a synergistic consequence of an Fg

57 Following EV injection, activated platelets accumulate particularly within the p

58 Activated platelets adhere to intravascular neutrophils

59 Activated platelets adhered were and ultimately digested

60 Activated platelets adherent to adsorbed mutant fibrinog

61 soluble fibronectin by lysophosphatidic acid-activated platelets adherent to fibrinogen or fibrin.

62 Many of these gaps contain activated platelets adhering to exposed basement membran

63 a Kunitz-type protease inhibitor secreted by activated platelets and a physiologically important inhi

64 icellular protein released in abundance from activated platelets and accumulated in sites of vascular

65 lymer of inorganic phosphate, is secreted by activated platelets and accumulates in many infectious m

66 actor Xa generation assay in the presence of activated platelets and cofactor factor VIIIa, compared

67 QGAP2 expression in filopodial extensions of activated platelets and colocalized with F-actin in lame

68 verexpressed 1 (CCN1) protein is released by activated platelets and enables the recruitment of Ly6C(

69 Leukocyte adhesion to P-selectin on activated platelets and endothelial cells induces sheddi

70 iates the initial tethering of leukocytes to activated platelets and endothelium.

71 und to albumin and is reported to arise from activated platelets and erythrocytes.

72 Polyphosphate (polyP) is secreted by activated platelets and has been shown to contribute to

73 CXCL4 is a chemokine abundantly produced by activated platelets and immune cells.

74 es human alphaIIbbeta3 on both quiescent and activated platelets and is enzymatically activated speci

75 and TLR4 with mAbs reduced the percentage of activated platelets and lowered the amount of thrombin g

76 ein thrombospondin-1 (hTSP-1) is released by activated platelets and mediates adhesion of Gram-positi

77 Polyphosphate (polyP) is released from activated platelets and mediates FXII activation.

78 rol MBs strongly adhered to both immobilized activated platelets and microthrombi under flow.

79 rgeted to the negatively charged surfaces of activated platelets and other cells, where it can serve

80 CF patients have an increase in circulating activated platelets and platelet reactivity, as determin

81 Recent studies have suggested that activated platelets and platelet thrombi can contribute

82 The presence of activated platelets and platelet-leukocyte aggregates in

83 LIPRs are formed downstream the adherent and activated platelets and reach lengths of 250 mum.

84 The combination of activated platelets and specific immunoglobulin G-adsorb

85 We prospectively determined whether activated platelets and systemic procoagulant factors we

86 he acquisition of proteins to the surface of activated platelets and the consequences for platelet im

87 ARCKS) bind to phosphatidylserine exposed on activated platelets and thereby inhibit fibrin formation

88 nvestigate a possible release of miRNAs from activated platelets and to elucidate whether platelet-de

89 P-selectin expressed on activated platelets and vascular endothelium mediates ad

90 h antibodies against neutrophils, platelets, activated platelets, and endothelium.

91 the TREM family, is selectively expressed on activated platelets, and is known to facilitate platelet

92 lectins (expressed by activated endothelium, activated platelets, and leukocytes) binding to their re

93 The released material activated platelets, and platelets co-aggregated with en

94 Microvesicles bound only activated platelets, and required PSGL-1 to do so.

95 s reveal that recruited neutrophils scan for activated platelets, and they suggest that the neutrophi

96 in vitro to selectin-coated dishes, thrombin-activated platelets, and tumor necrosis factor alpha-act

97 C1C2 binding to activated platelets appeared independent of von Willebra

98 Activated platelets are considered to provide the primar

99 Recent findings indicate that the activated platelets are crucial regulators of tumor vasc

100 glycoprotein (GP) IIb/IIIa on the surface of activated platelets are degraded by the serine protease

101 Activated platelets are known to modulate immune respons

102 ane-bound protease complex on the surface of activated platelets at the site of a vascular injury.

103 We report that thrombin-activated platelets, at physiologic concentration and pH

104 More than 90% of activated platelets bound C1C2, compared with approximat

105 hed FXI binding to HUVECs in the presence of activated platelets, but FXI did not influence PK bindin

106 ression was assessed in resting and thrombin-activated platelets by flow cytometry and in mucosal mic

107 demonstrated an increased phagocytosis of M1-activated platelets by monocytes, which was not observed

108 esults suggest that PS-mediated clearance of activated platelets by the endothelium results in an ant

109 imize the procoagulant activity expressed by activated platelets, by limiting the anticoagulant funct

110 Activated platelets can activate the complement system.

111 per, we show that the converse is also true: activated platelets can activate the complement system.

112 Activated platelets can also supply the sialic acid dono

113 timulate platelet production and activation; activated platelets can, in turn, promote tumor growth a

114 noids such as thromboxane A2 Releasates from activated platelets caused cell migration and tube forma

115 Elevated numbers of activated platelets circulate in patients with chronic i

116 es and all C5a-stimulated monocytes (but not activated platelets) completely convert factor VII to fa

117 Thus, activated platelets contribute to CTL-mediated liver imm

118 Recent findings that activated platelets contribute to the inflammatory disea

119 We hypothesized that activated platelets could also release their mitochondri

120 -3 is required for condensation of fibrin by activated platelets, demonstrating functional significan

121 Before surgery, cases had 2- and 4-fold more activated platelet-derived and tissue-factor positive MV

122 mammalian Nck adaptors in signaling from the activated platelet-derived growth factor (PDGF) receptor

123 1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-alpha

124 activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor.

125 Activated platelets display immobilized fibrinogen on th

126 inds to the glycoprotein IIb/IIIa present on activated platelets (DMP-444).

127 by thrombin in solution or on the surface of activated platelets does not appear to play a significan

128 xA(2)) is one of the mediators released from activated platelets during myocardial ischaemia.

129 The presence of activated platelets enabled the tPA-loaded, cRGD-coated,

130 on assay both in the presence and absence of activated platelets even at concentrations at which less

131 Activated platelets expose phosphatidylserine on their o

132 The recent demonstration that activated platelets express CD40 ligand (L) provides a m

133 In cadaver allografts with deposition of activated platelets expressing either P-selectin or vWF,

134 hosphatidylserine (PS)-exposing procoagulant-activated platelets followed by formation of the membran

135 We analyzed GPVI-activated platelets from ST-elevation myocardial infarct

136 ptor alphaIIbbeta3, was observed in thrombin-activated platelets from wild-type but not Gpx1 Tg mice

137 sence of low ADP levels, HMEC-1 supernatants activated platelet function assessed by classical aggreg

138 n of fluid shear to whole blood, half of the activated platelets had DeltaA1-488 bound, suggesting th

139 Prothrombinase assembled on the surface of activated platelets has been shown to proceed through th

140 Our findings suggest that activated platelets have anti-inflammatory properties re

141 GD is unclear, although both neutrophils and activated platelets have been implicated.

142 Proteomic experiments in resting and activated platelets have identified novel signaling path

143 Activated platelets have key thromboinflammatory activit

144 With activated platelets having mutual tensile action sustain

145 ed well only to GFOGER and GLOGER, while ADP-activated platelets, HT1080 cells and two active alpha(2

146 etting of hyperlipidemia and atherosclerosis activated platelets in a CD36-dependent manner.

147 ulated neutrophils avidly bound Ps-beads and activated platelets in an integrin-independent manner, s

148 hese monocyte-derived microparticles bind to activated platelets in an interaction mediated by platel

149 venues that might help elucidate the role of activated platelets in CF.

150 We conclude that the presence of activated platelets in circulation promotes acute inflam

151 The mechanisms that eliminate activated platelets in inflammation-induced disseminated

152 bility group box 1 (HMGB1) is upregulated by activated platelets in multiple inflammatory diseases; h

153 Ibalpha were able to inhibit FXI binding to activated platelets in the following order of decreasing

154 des circulate to remote injuries and bind to activated platelets in the inner core of developing thro

155 d to anionic phospholipids on the surface of activated platelets in the presence of calcium ions.

156 ,744), showed heparin-dependent binding, and activated platelets in the presence of protamine.

157 n IIb/IIIa-targeted MBs specifically bind to activated platelets in vitro and allow real-time molecul

158 monoclonal anti-CD40L immune complexes (ICs) activated platelets in vitro via the IgG receptor (Fcgam

159 ticles--submicrometer vesicles elaborated by activated platelets--in joint fluid from patients with r

160 megakaryocytes (MKs) with the releasate from activated platelets increased proplatelet production by

161 These findings demonstrate that activated platelets induce COX-2 synthesis in monocytes

162 Here, we report that activated platelets induce the formation of neutrophil e

163 sphate groups called polyphosphate, and when activated, platelets induce blood clotting (the first st

164 Conditioned medium from activated platelets induced an IL-1alpha-dependent activ

165 Activated platelets induced endothelial expression of IC

166 eby protects mitochondrial function, reduces activated platelet-induced mitochondrial hyperpolarizati

167 arterial thrombosis and protect animals from activated platelet-induced venous thromboembolism withou

168 eport that coculture of human monocytes with activated platelets induces phosphorylation of Akt, toge

169 lectin, a key adhesion molecule displayed by activated platelets, induces NF-kappaB activation and CO

170 In addition, activated platelets inhibited CD4(+) T cell proliferatio

171 The i.v. injection of thrombin-activated platelets into CD40(-/-)apoE(-/-) mice was per

172 Infusion of activated platelets into young mice led to the formation

173 on, suggesting that the NO production in the activated platelet is due to ATP.

174 riphosphate hydrolase activity (CD39) toward activated platelets is a promising new treatment concept

175 istic architecture in which a core of highly activated platelets is covered by a shell of less-activa

176 ion of an inflammatory monocyte phenotype by activated platelets is implicated in the pathogenesis of

177 moieties released from the dense granules of activated platelets, is a procoagulant agent.

178 splaced [125I]factor XIa from the surface of activated platelets (Ki approximately 5.8 nM), whereas a

179 was able to compete with FXI for binding to activated platelets (Ki of 3.125 +/- 0.25 nm) with a pot

180 sults in the formation of a subpopulation of activated platelets known as coated platelets.

181 infectious microorganisms and is secreted by activated platelets; long-chain polyphosphate in particu

182 Activated platelets made IL-1beta in vivo as IL-1beta ra

183 Microscopy reveals activated platelets, many containing viral particles and

184 Thus, targeting of activated platelets may allow for molecular imaging of v

185 suggest that binding of autotaxin/lysoPLD to activated platelets may provide a mechanism to localize

186 lyP and FXII were found to colocalize on the activated platelet membrane in a fibrin-dependent manner

187 for platelet FXIII-A through exposure on the activated platelet membrane where it exerts antifibrinol

188 in the FVIIIa-FIXa complex assembled on the activated platelet membrane.

189 possible role of platelet microparticles or activated platelet membranes, which carry a negative cha

190 Released Zn2+ from 2-8 x 10(8) collagen-activated platelets/ml supported biotin-FXI binding to H

191 HIT is propagated by activated platelets, monocytes, endothelial cells, and c

192 Activation of the alternative pathway on activated platelets occurs when properdin is on the surf

193 We examined the influence of activated platelets on cytokine production by normal hum

194 r actomyosin rearrangements and spreading of activated platelets on fibrinogen.

195 er demonstrate that the secondary capture of activated platelets on the plaque is predominantly media

196 donors, whereas microparticles derived from activated platelets only express CLEC-2.

197 ichiometry and affinity of FVIIIa binding to activated platelets only in the presence of FIXa and FX

198 Consistent with observed mRNA stabilization, activated platelets or IL-1beta treatment induced cytopl

199 Release of polyphosphate from activated platelets or infectious microorganisms may pla

200 ng microparticles are derived primarily from activated platelets or megakaryocytes, we identified mar

201 titrating factor X or factor VIIIa on SFLLRN-activated platelets or phospholipid vesicles revealed ne

202 PS was phosphorylated on exposure to activated platelets or their releasates, as judged by im

203 ascade by parasitized red blood cells and/or activated platelets (particularly at sequestration sites

204 complexes between inflammatory monocytes and activated platelets (PMCs), which are detected by flow c

205 These data show that histone-activated platelets possess a procoagulant phenotype tha

206 Pyrophosphate, which is also secreted by activated platelets, potently blocked polyphosphate-medi

207 to organize a protruding domain that engaged activated platelets present in the bloodstream.

208 Activated platelets promote cancer progression and metas

209 Activated platelets promote intrinsic factor X-activatin

210 Activated platelets provide a promising target for imagi

211 Activated platelets provide a surface for assembly of th

212 Thus, delayed targeting of CD39 via scFv to activated platelets provides strong antithrombotic poten

213 entification of novel signaling molecules in activated platelets, providing new insights into the mec

214 These data show that P-selectin on activated platelets rapidly triggers TF exposure on mono

215 In vitro, LPS-activated platelets rather than LPS alone efficiently in

216 (FIXa), factor VIII(a) [FVIII(a)], and FX to activated platelet receptors.

217 ed with either serum, DBP-depleted serum, or activated platelet releasate provides a required factor

218 Fractionation of activated platelet releasate revealed that the additiona

219 iciently killed by human platelets, thrombin-activated platelet releasate, and synthetic platelet-ass

220 We find that activated platelets release a factor that promotes fibro

221 We conclude that activated platelets release ADAMDEC1, which hydrolyzes p

222 We now show that activated platelets release glutamate, that platelets ex

223 Activated platelets release many inflammatory molecules

224 We show that activated platelets release respiratory-competent mitoch

225 Activated platelets release their granule content in a c

226 Activated platelets released high-molecular-weight (HMW)

227 Many of the cellular responses that occur in activated platelets resemble events that take place foll

228 Likewise, only thrombin-activated platelets resulted in rapid translocation of I

229 nfocal and electron microscopy, we show that activated platelets retain polyphosphate on their cell s

230 formation (NETosis) was induced by thrombin-activated platelets rosetting with neutrophils and was i

231 Activated platelets secrete a negatively charged polymer

232 Activated platelets secrete platelet-derived growth fact

233 Activated platelets secrete the highly anionic polymer p

234 These results suggest that the nano-sized, activated-platelet-sensitive, multifunctional liposomes

235 with MI exhibit loss of specific miRNAs, and activated platelets shed miRNAs that can regulate endoth

236 Activated platelets shed surface proteins, potentially m

237 More fibronectin was assembled by activated platelets spread on fibrin matrices than by pl

238 band likely function during both resting and activated platelet states.

239 Previous studies have shown that activated platelets stimulate ischaemically sensitive ca

240 lerosis made us address the question whether activated platelets stimulate normal healthy endothelium

241 cent studies have revealed that at least two activated platelet subpopulations are formed upon potent

242 Here, we demonstrate in vitro that activated platelets substantially inhibit recruitment of

243 domain significantly impaired Efb binding by activated platelets, suggesting that P-selectin is the m

244 d with [125I]factor XIa for binding sites on activated platelets, suggesting that the factor XIa bind

245 ent externalization of phosphatidylserine in activated platelets, suggesting that this homologue migh

246 ion studies and incubation of monocytes with activated platelet supernatant highlighted a role for se

247 that APC binds human leukocytes and prevents activated platelet supernatant or phorbol 12-myristate 1

248 latelet activation was assessed by measuring activated platelet surface expression of P-selectin and

249 m of the FVIIIa-FIXa complex assembly on the activated platelet surface in the propagation phase of b

250 formed when prothrombin is processed on the activated platelet surface, the cleavage of prothrombin,

251 omplex of factors Va and Xa assembled on the activated platelet surface, which cleaves prothrombin at

252 ens the initial prothrombinase formed on the activated platelet surface.

253 fragment, the most relevant of which is the activated platelet surface.

254 purified plasma-derived FVa on the thrombin-activated platelet surface.

255 2" domain is responsible for binding to both activated platelet surfaces and von Willebrand factor.

256 a on negatively charged membranes, including activated platelet surfaces.

257 evaluate the anti-inflammatory potential of activated platelet targeted nucleoside triphosphate hydr

258 d by natural killer (NK) cells as well as by activated platelets that express CD40L.

259 Activated platelets that expressed P-selectin attached t

260 on and signal-dependant protein synthesis in activated platelets that may contribute to thrombus and

261 In ITAM-activated platelets that were treated with a PI3K inhibi

262 The microvesicles not only bound the activated platelets, they fused with them, transferring

263 crophage-derived microvesicles that can bind activated platelets through a mechanism involving P-sele

264 llograft rejection can thus be instigated by activated platelets through CD154.

265 modulation of monocyte cytokine responses by activated platelets through P-selectin binding, we found

266 The ability of activated platelets to adhere to each other at sites of

267 labeled miRNA and exogenous cel-miR-39 from activated platelets to endothelial cells was shown.

268 nfer that platelet activation and binding of activated platelets to eosinophils followed by P-selecti

269 latelets and decreased the adhesion of Abeta-activated platelets to injured carotid arteries in mice.

270 ists, contribution of thrombin generation by activated platelets to the test results, and establishme

271 lot retraction refers to the process whereby activated platelets transduce contractile forces onto th

272 pathway-inhibited blood or plasma containing activated platelets, typically no clot is observed for 2

273 a promising strategy to support adhesion to activated platelets under arterial shear stress, these a

274 is necessary for stable bacterial binding to activated platelets under shear.

275 The tube surface is resistant to adhesion of activated platelets unlike planar control titania and sm

276 Activated platelets up-regulated expression of intercell

277 CD41 microparticles also form from activated platelets upon loss of cytoskeleton-membrane a

278 By analyzing basal and TRAP-activated platelets using 2-dimensional gel electrophore

279 Evaluation of SNARE protein localization in activated platelets using immunonanogold staining and el

280 lyzing protein fragments in the supernate of activated platelets using mass spectroscopy and looking

281 oside triphosphate hydrolase activity toward activated platelets via a recombinant fusion protein com

282 Release of sCD40L from activated platelets was also markedly reduced in Glanzma

283 Surface pro-IL-1alpha on macrophages and activated platelets was cleaved and activated by thrombi

284 lease of Weibel-Palade bodies on infusion of activated platelets was indicated by both elevation of p

285 wever, release of sCD40L from the surface of activated platelets was inhibited by GP IIb/IIIa antagon

286 In contrast, shedding of P-selectin from activated platelets was not affected by the mutation in

287 organized structure in which a core of fully activated platelets was overlaid with an unstable shell

288 FXIII-A activity on activated platelets was unstable and was rapidly lost ov

289 emarkably, all these inflammatory actions by activated platelets were abrogated by lack of CD40 on in

290 Activated platelets were detectable by magnetic resonanc

291 TE was 23 nm Additionally, lipid extracts of activated platelets were separated by RP-HPLC demonstrat

292 Activated platelets were targeted with a contrast agent

293 Factor XI binds to activated platelets where it is efficiently activated by

294 regates involved the interaction of CD62P on activated platelets with adhesion molecule CD166 on acti

295 in micelles that can be targeted to sites of activated platelets with broad potential for treatment o

296 ably, assembly of FXa(I16L) and FXa(V17A) on activated platelets with factor Va to form prothrombinas

297 ificantly increases complement deposition on activated platelets with surface properdin.

298 l proteomic analysis of basal and rhodocytin-activated platelets with the aim of providing novel clue

299 volving membrane fusion upon incubation with activated platelets within 1 h, whereas passive release

300 h microbubbles (MBs) selectively targeted to activated platelets would offer high-resolution, real-ti